Keytruda can be a brand (trade) name for pembrolizumab. It's given by intravenous infusion every three to 6 weeks. Rarely, the use of Keytruda results while in the immune system attacking nutritious tissues which can cause critical side effects for instance pneumonitis, colitis, or hepatitis. In lots of people, the usage of Keytruda has resulted in